D011993Chemicals & DrugsD12.776.828.3002485550.847914Recombinant Fusion Proteinsplugins:TwitterTwitterprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonJeffreyHubbell3Wp8CaMQFeD5hHlsaUXv9Gq0+s+oJeffrey Hubbell41.7886000000000087.598699999999993473Hubbell, JeffreyBarry L. MacLean ProfessorPritzker Institute for Molecular Engineering32552072Hussain RM, Weng CY, Wykoff CC, Gandhi RA, Hariprasad SMExpert opinion on biological therapyAbicipar pegol for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2020 09; 20(9):999-1008.Expert Opin Biol Ther2020-07-03T00:00:002020Abicipar pegol for neovascular age-related macular degeneration.33046864Ishihara A, Ishihara J, Watkins EA, Tremain AC, Nguyen M, Solanki A, Katsumata K, Mansurov A, Budina E, Alpar AT, Hosseinchi P, Maillat L, Reda JW, Kageyama T, Swartz MA, Yuba E, Hubbell JANature biomedical engineeringProlonged residence of an albumin-IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis. Nat Biomed Eng. 2021 05; 5(5):387-398.Nat Biomed Eng2020-10-12T00:00:002020Prolonged residence of an albumin-IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis.33169522Yuba E, Budina E, Katsumata K, Ishihara A, Mansurov A, Alpar AT, Watkins EA, Hosseinchi P, Reda JW, Lauterbach AL, Nguyen M, Solanki A, Kageyama T, Swartz MA, Ishihara J, Hubbell JAArthritis & rheumatology (Hoboken, N.J.)Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukin-10 in Murine Models. Arthritis Rheumatol. 2021 05; 73(5):769-778.Arthritis Rheumatol2021-03-08T00:00:002021Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukin-10 in Murine Models.Ben May Department of Cancer ResearchOphthalmology and Visual Sciencehttps://ophthalmology.uchicago.edu/The University of Chicago Department of Ophthalmologyhttp://retinatoday.com/2010/02/5-questions-with-seenu-m-hariprasad-md/5 QUESTIONS with Seenu M. Hariprasad, MDhttp://voices.uchicago.edu/rebaylab/Rebay Labhttps://ophthalmology.uchicago.edu/news/london-based-architect-and-cyclist-vision-renewedFor London-Based Architect and Cyclist, A Vision RenewedUChicagoOVS1.887920.00421085248research area of0.9920610.0195801567subject area forUniversity of ChicagoSeenuHariprasadSeenu Hariprasad41.78927490000000-87.601250000000002154Hariprasad, SeenuProfessorIlariaRebayIlaria Rebay41.78927490000000-87.601250000000002383Rebay, IlariaProfessorGregoryHudallaGregory Hudalla41.78927490000000-87.601250000000002592Hudalla, GregoryKennethGordonKenneth Gordon41.78927490000000-87.60125000000000340Gordon, Kenneth38049618Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Michel A, Latocha M, Schmidt-Ott UM, Lovic N, Brunck LR, Johnson KT, Suzart-Woischnik KPharmaceutical medicineEvaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization Materials. Pharmaceut Med. 2024 Jan; 38(1):63-73.Pharmaceut Med2023-12-05T00:00:002023Evaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization Materials.38109213Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJClinical cancer research : an official journal of the American Association for Cancer ResearchNeoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.Clin Cancer Res2024-02-16T00:00:002024Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.true1true1true1ProfessorProfessortrue1ProfessorProfessortrue1Barry L. MacLean ProfessorBarry L. MacLean Professor